Skip to content
Subscriber Only

Roche’s Avastin Drug Fails to Add Time in Brain Cancer Study

Roche Holding AG’s Avastin failed to extend the survival of patients with deadly brain tumors in a study that found no advantage in using the drug as a first-line therapy against the cancer known as glioblastoma.

In separate findings, the $6-billion-a-year treatment helped prolong the lives of women with an aggressive form of cervical cancer. Results from both trials were presented yesterday at the American Society of Clinical Oncology meeting in Chicago.